^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BLU-222

    i
    Company:
    Blueprint Medicines, UT MD Anderson Cancer Center
    Drug class:
    CDK2 inhibitor
    Related drugs:
    Apply
    (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416)
    Phase 1/2
    Blueprint Medicines Corporation
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    04/07/2022
    Primary completion :
    11/30/2025
    Completion :
    09/30/2026
    HER-2 • CCNE1
    |
    HER-2 negative • CCNE1 amplification
    |
    carboplatin • Kisqali (ribociclib) • fulvestrant • BLU-222